<SEC-DOCUMENT>0001193125-18-000596.txt : 20180102
<SEC-HEADER>0001193125-18-000596.hdr.sgml : 20180102
<ACCEPTANCE-DATETIME>20180102160555
ACCESSION NUMBER:		0001193125-18-000596
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171228
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180102
DATE AS OF CHANGE:		20180102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		18501818

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d501518d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;28, 2017 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2017, Inovio
Pharmaceuticals, Inc. (the &#147;<B><I>Registrant</I></B>&#148;) entered into an Amended and Restated License and Collaboration Agreement (the &#147;<B><I>License and Collaboration Agreement</I></B>&#148;) with Beijing Apollo Saturn Biological
Technology Limited, a corporation organized under the laws of China (&#147;<B><I>ApolloBio</I></B>&#148;). Under the terms of the License and Collaboration Agreement, the Registrant has granted to ApolloBio the exclusive right to develop and
commercialize <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> the Registrant&#146;s DNA immunotherapy product designed to treat <FONT STYLE="white-space:nowrap">pre-cancers</FONT> caused by human papillomavirus, or HPV, within the territories of
China, Hong Kong, Macao and Taiwan. The territory may be expanded to include Korea in the event that no patent covering <FONT STYLE="white-space:nowrap">VGX-3100</FONT> issues in China within the three years following the Effective Date (as defined
below). As part of the collaboration, the parties will discuss in good faith the inclusion of clinical trial sites in China as part of the Registrant&#146;s ongoing Phase 3 clinical development program for
<FONT STYLE="white-space:nowrap">VGX-3100.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the License and Collaboration Agreement, the Registrant has granted to
ApolloBio an option to negotiate an exclusive license to research, develop and commercialize the Registrant&#146;s product candidate <FONT STYLE="white-space:nowrap">INO-3112</FONT> in the event of termination of the Registrant&#146;s current
collaboration with MedImmune for the development of <FONT STYLE="white-space:nowrap">INO-3112</FONT> in the territory covered by the License and Collaboration Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the License and Collaboration Agreement, ApolloBio will pay to the Registrant an upfront payment of $23.0&nbsp;million, such payment to
be made within three business days following the date of approval of the License and Collaboration Agreement by the board of directors and shareholders of ApolloBio (the &#147;<B><I>Effective Date</I></B>&#148;), which Effective Date is expected to
occur in the first quarter of 2018. In the event that such upfront payment is not made on or before April&nbsp;7, 2018, the Registrant has the right to terminate the License and Collaboration Agreement in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the upfront payment, the Registrant is entitled to receive up to an aggregate of $20.0&nbsp;million upon the achievement of
specified milestones related to the regulatory approval of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> in the United States, China and Korea. In the event that <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is approved for marketing, the
Registrant will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-teens,</FONT> subject to
reduction in the event of generic competition in a particular territory. ApolloBio&#146;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> patent covering the licensed products in the specified territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations. Either
party may terminate the License and Collaboration Agreement in the event the other party shall have materially breached or defaulted in the performance of its material obligations thereunder and such default shall have continued for a specified
period after written notice thereof. In addition, ApolloBio may terminate the License and Collaboration Agreement at any time beginning one year after the Effective Date for any reason upon 90 days&#146; written notice to the Registrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the License and Collaboration Agreement is not complete and is qualified in its entirety by reference to the License
and Collaboration Agreement, a copy of which will be filed as an exhibit to the Registrant&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ending December&nbsp;31, 2017. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 2, 2018, the Registrant issued a press release
announcing its entry into the License and Collaboration Agreement. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. &nbsp;&nbsp;&nbsp;&nbsp; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed in Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed on July&nbsp;14, 2017 and November&nbsp;1, 2017, the Registrant and ApolloBio had entered into a stock purchase agreement (the &#147;<B><I>Purchase Agreement</I></B>&#148;) pursuant to which ApolloBio had
the right to purchase up to $35.0&nbsp;million of the Registrant&#146;s common stock upon the satisfaction of the closing conditions set forth in the Purchase Agreement. In connection with the execution of the License and Collaboration Agreement,
the Registrant and ApolloBio have terminated the Purchase Agreement prior to it becoming effective. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d501518dex991.htm">Press Release, dated January 2, 2018, &#147;Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize <FONT STYLE="white-space:nowrap">VGX-3100</FONT> in Greater China.&#148;
</A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>INOVIO&nbsp;PHARMACEUTICALS,&nbsp;INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;2, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Kies</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d501518dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g501518g0102055412249.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>NEWS RELEASE</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immediate Release </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Ben Matone, Inovio, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com </U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jeff Richardson, Inovio, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U>
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Enters License and Collaboration Agreement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with ApolloBio To Develop and Commercialize </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">VGX-3100</FONT> in Greater China </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio to receive $23&nbsp;million in upfront payment; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>an additional $20&nbsp;million in future regulatory milestone payments </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and double-digit tiered royalties on sales </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; January&nbsp;2, 2018 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it entered an amended agreement
providing ApolloBio Corporation (NEEQ: 430187) with the exclusive right to develop and commercialize <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> Inovio&#146;s DNA immunotherapy product designed to treat
<FONT STYLE="white-space:nowrap">pre-cancers</FONT> caused by human papillomavirus (HPV), within Greater China (China, Hong Kong, Macao, Taiwan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based
on the new agreement, ApolloBio will make an upfront payment of $23&nbsp;million (an increase from the previously announced amount of $15 million), as well as potential future payments up to $20<U></U>&nbsp;million upon meeting certain milestones.
In addition, Inovio is entitled to receive double-digit tiered royalty payments on sales. As part of the new terms which replace the previous amendments to this agreement that were announced on November<U></U>&nbsp;2, 2017, the parties have agreed
to terminate ApolloBio&#146;s right to purchase Inovio stock. This collaboration of VGX-3100 encompasses the treatment and/or prevention of pre-cancerous HPV infections and <FONT STYLE="white-space:nowrap">HPV-driven</FONT> dysplasias (including
cervical, vulvar and anal <FONT STYLE="white-space:nowrap">pre-cancers)</FONT> and excludes <FONT STYLE="white-space:nowrap">HPV-driven</FONT> cancers and all combinations of <FONT STYLE="white-space:nowrap">VGX-3100</FONT> with other
immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the next three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim,
Inovio&#146;s President and Chief Executive Officer, said, &#147;ApolloBio is an excellent partner that brings significant capabilities and expertise relating to product development, the Chinese regulatory landscape, and the healthcare marketplace
in China. We are pleased to move forward with an agreement that preserves the best interest for our shareholders by obtaining a greater upfront <FONT STYLE="white-space:nowrap">non-dilutive</FONT> cash license fee of $23<U></U>&nbsp;million and
removing the equity provisions. In addition, this collaborative agreement with ApolloBio could potentially accelerate our overall global <FONT STYLE="white-space:nowrap">VGX-3100</FONT> efforts by accessing clinical study patients in China. We
expect this deal to close in the first quarter of 2018.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Weiping Yang, Chief Executive Officer of ApolloBio, said, &#147;This license and
collaboration agreement marks our determination to introduce late stage innovative new drugs to meet severely unmet medical needs within the Greater China region. We are excited at the potential for <FONT STYLE="white-space:nowrap">VGX-3100</FONT>
to address multiple indications within <FONT STYLE="white-space:nowrap">HPV-associated</FONT> <FONT STYLE="white-space:nowrap">pre-cancer,</FONT> and we very pleased to be launching this strategic collaboration with Inovio, an innovative global
biotechnology partner.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">VGX-3100</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">VGX-3100</FONT> is an <FONT STYLE="white-space:nowrap">HPV-specific</FONT> immunotherapy that is being developed as a <FONT
STYLE="white-space:nowrap">non-surgical</FONT> treatment for high-grade cervical dysplasia and related underlying persistent HPV infection. <FONT STYLE="white-space:nowrap">VGX-3100</FONT> works in vivo to activate functional, antigen-specific, <FONT
STYLE="white-space:nowrap">CD-8</FONT> <FONT STYLE="white-space:nowrap">T-cells</FONT> to clear persistent HPV 16/18 infection and cause regression of <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> cervical dysplasia. In a phase 2b trial, <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> demonstrated clinical efficacy and was generally well tolerated, without the side effects and obstetric risks associated with surgical excision. <FONT STYLE="white-space:nowrap">VGX-3100</FONT> is a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">HPV-specific</FONT> immunotherapy that targets the underlying cause of cervical dysplasia, providing an opportunity for women
to reduce their risk of cervical cancer without undergoing an invasive surgical procedure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About HPV and Cervical Dysplasia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which kills more than 250,000 women every year worldwide. Among
the 300<U></U>&nbsp;million women currently infected with HPV, 500,000 will be diagnosed with cervical cancer each year. Two types of HPV (HPV 16 and HPV 18) cause 70% of cervical cancer cases. High-grade cervical dysplasia is also caused by
persistent HPV infection and is a pre-cancerous condition that can progress to cervical cancer if left untreated. Globally the number of high-grade cervical dysplasia cases is estimated to be in the range of 10<U></U>&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently there are no approved medical treatments for persistent HPV infection or cervical dysplasia. The primary treatment for high-grade cervical dysplasia
is surgical excision of the <FONT STYLE="white-space:nowrap">pre-cancerous</FONT> lesion and a margin of healthy cervical tissue. Because surgical excision does not treat the underlying HPV infection that causes cervical dysplasia, there is a <FONT
STYLE="white-space:nowrap">10-16%</FONT> risk of disease recurrence. Women with persistent HPV infection after surgical excision remain at high risk for cervical cancer. In addition, surgical treatment is associated with pain and cramping, and a
risk for post-surgical bleeding, infection, and <FONT STYLE="white-space:nowrap">pre-term</FONT> delivery and miscarriages during future pregnancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ApolloBio Corp. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ApolloBio Corp. (NEEQ: 430187) is
a leading Chinese biomedical company committed to research and development of innovative new medicines, accessing such new medicines through <FONT STYLE="white-space:nowrap">in-licensing,</FONT> and additionally providing medical services. ApolloBio
Corp. is focused on pharmaceutical products with significant market potential in China in the field of oncology; providing efficient access for American biomedical companies to enter into the Chinese market; and aiming to bring the newest and best
medicines across the globe to the Chinese people. For more information, visit www.apollobio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported
generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a
growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio
Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit <U>www.inovio.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned
initiation and conduct of clinical trials and the availability and timing of data from those trials, and the sufficiency of our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of
factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, the </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we
license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the
company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents
and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s
technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December<U></U>&nbsp;31, 2016, our Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended September 30, 2017, and other regulatory filings we make from time to time. There can be no assurance that any product candidate
in Inovio&#146;s pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking
information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Inovio undertakes no obligation to update or revise these statements, except as may be required by law. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g501518g0102055412249.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g501518g0102055412249.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ 04# 2(  A$! Q$!_\0
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MZ_X_C7,_$NV0V5C=X&])3'GU!&?Z5'\,IV\O4K<GY0R2 >Y!!_D* ._HHHH
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DMI33R1//-<7!7SKBXE,DC[?NC)Z 9. ,#D^IH T:*** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
